within Pharmacolibrary.Drugs.ATC.L;

model L01EE04
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.62,
    Cl             = 15.9 / 1000 / 60,
    adminDuration  = 600,
    adminMass      = 25 / 1000000,
    adminCount     = 1,
    Vd             = 0.0294,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0139,
    Tlag           = 10.200000000000001
  );

  annotation(Documentation(
    info ="<html><body><p>Selumetinib is a selective inhibitor of MEK1/2 (mitogen-activated protein kinase kinases 1 and 2) used in the treatment of neurofibromatosis type 1-related symptomatic, inoperable plexiform neurofibromas in pediatric patients. Selumetinib is approved for medical use in several regions and is administered orally.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported for adult patients and pediatric patients with neurofibromatosis type 1. Values below are extracted from published population PK analysis and clinical studies in adults or children with cancer.</p><h4>References</h4><ol><li><p>Dombi, E, et al., &amp; Widemann, BC (2016). Activity of Selumetinib in Neurofibromatosis Type 1-Related Plexiform Neurofibromas. <i>The New England journal of medicine</i> 375(26) 2550–2560. DOI:<a href=&quot;https://doi.org/10.1056/NEJMoa1605943&quot;>10.1056/NEJMoa1605943</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/28029918/&quot;>https://pubmed.ncbi.nlm.nih.gov/28029918</a></p></li><li><p>Campagne, O, et al., &amp; Stewart, CF (2021). Clinical Pharmacokinetics and Pharmacodynamics of Selumetinib. <i>Clinical pharmacokinetics</i> 60(3) 283–303. DOI:<a href=&quot;https://doi.org/10.1007/s40262-020-00967-y&quot;>10.1007/s40262-020-00967-y</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33354735/&quot;>https://pubmed.ncbi.nlm.nih.gov/33354735</a></p></li><li><p>Dymond, AW, et al., &amp; Marbury, T (2017). Pharmacokinetics of a Single Oral Dose of the MEK1/2 Inhibitor Selumetinib in Subjects With End-Stage Renal Disease or Varying Degrees of Hepatic Impairment Compared With Healthy Subjects. <i>Journal of clinical pharmacology</i> 57(5) 592–605. DOI:<a href=&quot;https://doi.org/10.1002/jcph.848&quot;>10.1002/jcph.848</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/28019010/&quot;>https://pubmed.ncbi.nlm.nih.gov/28019010</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end L01EE04;
